[go: up one dir, main page]

MX2011011126A - Composiciones y metodos para tratar quemaduras. - Google Patents

Composiciones y metodos para tratar quemaduras.

Info

Publication number
MX2011011126A
MX2011011126A MX2011011126A MX2011011126A MX2011011126A MX 2011011126 A MX2011011126 A MX 2011011126A MX 2011011126 A MX2011011126 A MX 2011011126A MX 2011011126 A MX2011011126 A MX 2011011126A MX 2011011126 A MX2011011126 A MX 2011011126A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treating burns
cytokine
administering
Prior art date
Application number
MX2011011126A
Other languages
English (en)
Inventor
Terry Lee Hicks
Original Assignee
Mindcake Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mindcake Llc filed Critical Mindcake Llc
Publication of MX2011011126A publication Critical patent/MX2011011126A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención provee composiciones y métodos para tratar quemaduras que comprenden la administración en el área quemada de un sujeto en la necesidad del mismo de una cantidad terapéuticamente efectiva de una composición que comprende un agente anti-citosina o antiinflamatorio o un derivado funcional del mismo; y un portador farmacéuticamente aceptable.
MX2011011126A 2009-04-23 2010-04-15 Composiciones y metodos para tratar quemaduras. MX2011011126A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/429,169 US20100266709A1 (en) 2004-12-16 2009-04-23 Compositions and Methods for Treating Burns
PCT/US2010/031315 WO2010123759A2 (en) 2009-04-23 2010-04-15 Compositions and methods for treating burns

Publications (1)

Publication Number Publication Date
MX2011011126A true MX2011011126A (es) 2012-04-02

Family

ID=43011691

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011126A MX2011011126A (es) 2009-04-23 2010-04-15 Composiciones y metodos para tratar quemaduras.

Country Status (11)

Country Link
US (1) US20100266709A1 (es)
EP (1) EP2429535A2 (es)
JP (1) JP2012524782A (es)
KR (1) KR20120013404A (es)
CN (1) CN102438633A (es)
AU (1) AU2010239515A1 (es)
BR (1) BRPI1015539A2 (es)
CA (1) CA2760359A1 (es)
IL (1) IL215932A0 (es)
MX (1) MX2011011126A (es)
WO (1) WO2010123759A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934553A2 (en) * 2012-12-24 2015-10-28 DASCALU, Avi Compositions of aluminum fluoride and methods of use thereof for the treatment and prevention of actinic keratosis and sun-induced damages
KR101593208B1 (ko) * 2014-05-13 2016-02-12 주식회사 티앤엘 에어로졸 스프레이형 하이드로겔 화상치료제
CN121177507A (zh) 2016-08-12 2025-12-23 L.E.A.F.控股集团公司 α和γ-D聚谷氨酸化抗叶酸剂及其用途
US20180236098A1 (en) 2016-08-12 2018-08-23 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
KR101792535B1 (ko) 2017-09-27 2017-11-02 오상자이엘 주식회사 화상 치료용 키트
WO2019157121A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated lometrexol and uses thereof
WO2019157123A1 (en) * 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
EP3749311A4 (en) 2018-02-07 2022-07-06 L.E.A.F Holdings Group LLC PEMETREXED POLYGLUTAMATE GAMMA COMPOSITIONS AND THEIR USES
EP3749313A4 (en) 2018-02-07 2022-03-16 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATE ANTIFOLATES AND ASSOCIATED USES
CA3090506A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated tetrahydrofolates and uses thereof
WO2019157129A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
US11779584B2 (en) 2018-02-07 2023-10-10 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
WO2019157140A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Gamma polyglutamated raltitrexed and uses thereof
EP3749314A4 (en) 2018-02-07 2022-02-23 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATE METHOTREXATE AND ITS USES
WO2019157133A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
US12048767B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
WO2019160733A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated methotrexate and uses thereof
US12350271B2 (en) 2018-02-14 2025-07-08 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
CA3090875A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
US12048766B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
KR102313197B1 (ko) * 2018-07-11 2021-10-18 강형철 고체상염의 삼투작용으로 수포형성을 억제하는 화상 응급처치용 치료 제제 및 이를 포함하는 패치
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2352895A1 (fr) * 1976-04-21 1977-12-23 Diversey France Nouveau procede de traitement de surfaces metalliques au moyen de composes oxyfluores du phosphore 5
US4342857A (en) * 1980-12-31 1982-08-03 Colgate-Palmolive Company Antigingivitis composition comprising vinyl phosphonic acid/vinyl phosphonyl fluoride copolymer
US4490529A (en) * 1983-09-06 1984-12-25 Dana-Farber Cancer Institute, Inc. Cysteic acid and homocysteic acid analogues of methotrexate and aminopterin
US4828832A (en) * 1983-09-07 1989-05-09 Laboratorios Biochemie De Mexico Method of manufacturing a composition for treating skin lesions
US4632920A (en) * 1984-09-27 1986-12-30 University Of Medicine & Dentistry Of New Jersey Process for treating a warm-blooded animal following burn injury
US5863938A (en) * 1991-03-01 1999-01-26 Warner Lambert Company Antibacterial-wound healing compositions and methods for preparing and using same
US5674912A (en) * 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
US5602183A (en) * 1991-03-01 1997-02-11 Warner-Lambert Company Dermatological wound healing compositions and methods for preparing and using same
US5641814A (en) * 1991-03-01 1997-06-24 Warner-Lambert Company Antikeratolytic-wound healing compositions and methods for preparing and using same
US5489435A (en) * 1993-07-06 1996-02-06 Ratcliff; Perry A. Composition for treatment of abnormal conditions of the epithelium of bodily orifices
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
US5807541A (en) * 1996-04-22 1998-09-15 Sepracor, Inc. NSAID/fluoride periodontal compositions and methods
AU755564B2 (en) * 1998-06-20 2002-12-12 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6093743A (en) * 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6660306B2 (en) * 2000-10-12 2003-12-09 Mickey L. Peshoff Wound healing compound
CA2480082A1 (en) * 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
CA2405241C (en) * 2002-09-24 2011-07-26 Nova Chemicals Corporation Olefin polymerization catalyst system
JP2007507512A (ja) * 2003-09-30 2007-03-29 コーヒ コーポレーション 熱傷を治療するための組成物および方法

Also Published As

Publication number Publication date
WO2010123759A9 (en) 2011-02-17
KR20120013404A (ko) 2012-02-14
JP2012524782A (ja) 2012-10-18
CN102438633A (zh) 2012-05-02
EP2429535A2 (en) 2012-03-21
US20100266709A1 (en) 2010-10-21
BRPI1015539A2 (pt) 2019-07-09
CA2760359A1 (en) 2010-10-28
WO2010123759A2 (en) 2010-10-28
AU2010239515A1 (en) 2011-12-15
IL215932A0 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
MX2011011126A (es) Composiciones y metodos para tratar quemaduras.
MX2010009623A (es) Derivados de 1-bencil-3-hidroximetilindazol novedosos y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
SG158870A1 (en) Bendamustine pharmaceutical compositions for lyophilisation
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
MD4539B1 (ro) 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
SG10201908757TA (en) Boronic acids and esters as inhibitors of fatty amide hydrolase
MX2010009625A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
MX2009010170A (es) Formulaciones topicas que tienen biodisponibilidad aumentada.
IL197574A0 (en) Pharmaceutical compositions
MX357801B (es) Agentes dirigidos a gadd45beta.
WO2008157537A3 (en) Compositions and methods of use for treating or preventing lipid related disorders
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
MX2011009033A (es) Inhibidores triciclicos de cinasa pirazolopiridina.
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
WO2005032470A3 (en) Compositions and methods for treating burns
TNSN07193A1 (en) Pharmaceutical compositions comprising a camptothecin derivate
DOP2011000055A (es) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos
WO2012177653A3 (en) Targeting the neuromuscular junction for treatment
EP2040726A4 (en) COMPOSITION OF TRACHELOSPERMI CAULIS EXTRACT FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES
WO2010030976A3 (en) Methods and compositions for inhibiting atherosclerosis and vascular inflammation
EA201270747A1 (ru) Композиции и способы для профилактики и лечения ран
BR112013006651A2 (pt) composição e cocristal de aprepitante l-prolina
MY156278A (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
MX2010004620A (es) Derivados de benzomorfolina y metodos de uso.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal